Moderna (MRNA)
(Delayed Data from NSDQ)
$122.45 USD
-15.15 (-11.01%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $121.75 -0.70 (-0.57%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$122.45 USD
-15.15 (-11.01%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $121.75 -0.70 (-0.57%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Here's Why You Should Invest in Vertex (VRTX) Stock Now
by Zacks Equity Research
Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
Moderna (MRNA) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $125.62, marking a -0.04% move from the previous day.
Why Novavax's (NVAX) COVID Vaccine Struggles for Market Share?
by Zacks Equity Research
Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.
EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster
by Zacks Equity Research
The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.
Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids
by Zacks Equity Research
Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $122.15 in the latest trading session, marking a -0.07% move from the prior day.
Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19 booster vaccine in kids. The vaccine is already authorized for use in adolescents and adults.
Why Novavax (NVAX) Stock Was Down 13% on Thursday
by Zacks Equity Research
Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $124.32, marking a -1.15% move from the previous day.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.
Vaccine Stocks Down After Biden Says Pandemic is Over
by Kinjel Shah
BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.
Company News for Sep 20, 2022
by Zacks Equity Research
Companies in The News Are: WIX,COIN,TBPH,GSK,MRNA
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $137.74, marking a +1.38% move from the previous day.
Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine
by Zacks Equity Research
Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.
Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults
by Zacks Equity Research
Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.
Strength Seen in Galapagos NV (GLPG): Can Its 8% Jump Turn into More Strength?
by Zacks Equity Research
Galapagos NV (GLPG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $142.33, moving +0.74% from the previous trading session.
Stock Market News for Sep 9, 2022
by Zacks Equity Research
Wall Street closed higher on Thursday, led by a rally in finance and healthcare stocks.
Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland
by Zacks Equity Research
Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.
Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation
by Zacks Equity Research
The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.
Moderna (MRNA) Down 28.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion
by Ekta Bagri
Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.